Advisors Asset Management’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$220K Buy
+971
New +$173K ﹤0.01% 1143
2025
Q4
Sell
-2,627
Closed -$411K 1460
2025
Q3
$411K Sell
2,627
-41
-2% -$6.51K 0.01% 1007
2025
Q2
$405K Sell
2,668
-90
-3% -$12K 0.01% 985
2025
Q1
$415K Sell
2,758
-58
-2% -$9.72K 0.01% 973
2024
Q4
$520K Sell
2,816
-610
-18% -$118K 0.01% 915
2024
Q3
$675K Sell
3,426
-167
-5% -$34.7K 0.01% 839
2024
Q2
$742K Buy
3,593
+234
+7% +$53K 0.01% 797
2024
Q1
$910K Buy
3,359
+1,126
+50% +$269K 0.02% 758
2023
Q4
$528K Sell
2,233
-1,169
-34% -$230K 0.01% 883
2023
Q3
$667K Sell
3,402
-90
-3% -$18.5K 0.01% 827
2023
Q2
$734K Sell
3,492
-3,107
-47% -$618K 0.01% 836
2023
Q1
$1.33M Sell
6,599
-139
-2% -$31.5K 0.03% 655
2022
Q4
$1.47M Sell
6,738
-5,105
-43% -$1.11M 0.03% 599
2022
Q3
$2.33M Sell
11,843
-4,112
-26% -$888K 0.05% 454
2022
Q2
$3.41M Sell
15,955
-5,523
-26% -$1.35M 0.06% 331
2022
Q1
$6.1M Sell
21,478
-527
-2% -$163K 0.09% 227
2021
Q4
$8.29M Buy
22,005
+52
+0.2% +$20.2K 0.12% 177
2021
Q3
$9.06M Buy
21,953
+2,385
+12% +$991K 0.14% 144
2021
Q2
$7.24M Buy
19,568
+4,595
+31% +$1.53M 0.1% 204
2021
Q1
$4.34M Sell
14,973
-196
-1% -$54.5K 0.07% 291
2020
Q4
$3.79M Buy
15,169
+3,271
+27% +$779K 0.06% 325
2020
Q3
$2.69M Buy
11,898
+3,088
+35% +$641K 0.05% 359
2020
Q2
$1.54M Buy
8,810
+2,599
+42% +$415K 0.03% 556
2020
Q1
$784K Sell
6,211
-1,337
-18% -$201K 0.02% 687
2019
Q4
$1.15M Sell
7,548
-729
-9% -$101K 0.02% 708
2019
Q3
$1.1M Sell
8,277
-4,731
-36% -$634K 0.02% 721
2019
Q2
$1.85M Sell
13,008
-878
-6% -$119K 0.03% 576
2019
Q1
$2.02M Buy
13,886
+2,478
+22% +$326K 0.04% 540
2018
Q4
$1.29M Sell
11,408
-155
-1% -$19.4K 0.03% 676
2018
Q3
$1.56M Sell
11,563
-123
-1% -$15.2K 0.03% 690
2018
Q2
$1.31M Buy
11,686
+3,396
+41% +$367K 0.02% 747
2018
Q1
$884K Sell
8,290
-1,923
-19% -$207K 0.01% 883
2017
Q4
$1.12M Sell
10,213
-1,239
-11% -$135K 0.02% 803
2017
Q3
$1.24M Buy
11,452
+11,129
+3,446% +$1.14M 0.02% 776
2017
Q2
$33K Buy
+323
New +$29.7K ﹤0.01% 1462
2017
Q1
Sell
-16,941
Closed -$1.29M 1596
2016
Q4
$1.29M Sell
16,941
-2,499
-13% -$190K 0.02% 805
2016
Q3
$1.62M Sell
19,440
-16,202
-45% -$1.36M 0.03% 694
2016
Q2
$2.94M Sell
35,642
-4,196
-11% -$346K 0.05% 533
2016
Q1
$3.02M Sell
39,838
-18,373
-32% -$1.36M 0.05% 514
2015
Q4
$4.68M Sell
58,211
-6,818
-10% -$492K 0.07% 378
2015
Q3
$4.13M Buy
65,029
+3,906
+6% +$280K 0.07% 405
2015
Q2
$4.3M Buy
61,123
+6,448
+12% +$477K 0.06% 432
2015
Q1
$4.33M Buy
54,675
+14,635
+37% +$1.08M 0.06% 420
2014
Q4
$2.55M Buy
40,040
+7,886
+25% +$494K 0.03% 563
2014
Q3
$1.92M Buy
32,154
+6,775
+27% +$388K 0.03% 637
2014
Q2
$1.36M Buy
25,379
+9,965
+65% +$547K 0.02% 726
2014
Q1
$930K Buy
15,414
+5,776
+60% +$337K 0.01% 796
2013
Q4
$511K Sell
9,638
-909
-9% -$45.7K 0.01% 955
2013
Q3
$488K Sell
10,547
-1,874
-15% -$86K 0.01% 903
2013
Q2
$510K Buy
+12,421
New +$532K 0.01% 849

Other funds holding CRL

Advisors Asset Management's CRL Position: Q2 2026 in Review

Advisors Asset Management opened a new position in Charles River Laboratories (CRL) in Q2 2026: 971 shares worth $220K. The stake represents ﹤0.01% of the portfolio and ranks #1143 among its holdings. This is a return to the name: Advisors Asset Management previously reported a position in CRL as recently as Q3 2025.

Advisors Asset Management first reported a position in CRL in Q2 2013 and has held it in 50 quarters since. The position peaked at $9.06M in Q3 2021. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Advisors Asset Management held 971 shares of Charles River Laboratories worth $220K as of Q2 2026.
  • Charles River Laboratories was a new Advisors Asset Management position in Q2 2026.
  • Charles River Laboratories made up ﹤0.01% of Advisors Asset Management's portfolio in Q2 2026, its #1143 holding.
  • Advisors Asset Management first reported a position in Charles River Laboratories in Q2 2013 and has held it in 50 quarters since.
  • Advisors Asset Management's Charles River Laboratories position peaked at $9.06M in Q3 2021.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Advisors Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.